Home › Breast Cancer › Pennsylvania
Breast Cancer clinical trials in Pennsylvania
91 studies for Breast Cancer are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
- Philadelphia51 studies
- Pittsburgh42 studies
- Harrisburg11 studies
- Allentown10 studies
- York7 studies
- Scranton6 studies
- Reading5 studies
- Lancaster4 studies
- Hazleton4 studies
- Chambersburg4 studies
- Erie3 studies
- New Castle3 studies
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- St. Luke's University Health Network, Bethlehem
- Penn State Milton S. Hershey Medical Center, Hershey
- Guthrie Medical Group, Sayre
RecruitingPhase 1
Ages 18 to 55 · Women · Updated Nov 12, 2026 · NCT07310420A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
- Magee Womens Hospital, Pittsburgh
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 12, 2026 · NCT07541079S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Penn State Milton S Hershey Medical Center, Hershey
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03418961Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Nov 12, 2026 · NCT05372640Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
- Research Facility, Philadelphia
- Research Facility, Pittsburgh
RecruitingPhase 1/2
All ages · All sexes · Updated Nov 12, 2026 · NCT06590857Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
- Abramson Cancer Center, Philadelphia
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT05964504A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07029399Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Penn State Milton S. Hershey Medical Center, Hershey
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06324357Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Allegheny (AHN), Pittsburgh
Recruiting
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07214532Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- University of Pennsylvania, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT05315700A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- St. Luke's University Health Network, Bethlehem
- Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster
- University of Pennsylvania Hospital, Philadelphia
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07174336A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- UPMC Hillman Cancer Center - Magee-Women?s Hospital, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06790693E-Mindfulness Approaches for Living After Breast Cancer
- Carlisle Regional Cancer Center, Carlisle
- WellSpan Medical Oncology and Hematology, Chambersburg
- Geisinger Medical Center, Danville
- and 28 more
RecruitingPhase 3
Ages 18 to 50 · All sexes · Updated Nov 4, 2026 · NCT06748222Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Geisinger Medical Center, Danville
- and 7 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Alliance Cancer Specialist, Doylestown
- Allegheny Health Network, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05579366Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- WellSpan Medical Oncology and Hematology, Chambersburg
- and 13 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06418204A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- University of Pennsylvania, Philadelphia
- Fox Chase Cancer Center, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07213791A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- University of Pittsburgh Medical Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07114601Distance-Based Exercise to Preserve Function and Prevent Disability
- UPMC Hillman Cancer Center at Butler Health System, Butler
- UPMC Hillman Cancer Center - Passavant - Cranberry, Cranberry Township
- IRMC Cancer Center, Indiana
- and 6 more
Recruiting
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07059884Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Bryn Mawr Hospital, Bryn Mawr
- and 57 more
RecruitingPhase 3
Ages 18 to 60 · Women · Updated Nov 4, 2026 · NCT05879926A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0058), Pittsburgh
- Cancer Care Associates Of York ( Site 0063), York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07060807The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Penn Medicine - Lancaster General Hospital, Lancaster
- Capital Health Hematology Oncology Specialists, Newton
- Penn Medicine - Perelman Center for Advanced Medicine, Philadelphia
- and 2 more
RecruitingPhase 3
Ages 60 and older · All sexes · Updated Nov 2, 2026 · NCT06377852Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
- University of Pittsburgh Medical Center, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07524322A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia
- UPMC, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06774963EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
- Penn State Health Medical Group - Andrews Patel, Harrisburg
- Penn State Cancer Institute, Hershey
- UPMC Magee - Womens Hospital, Pittsburgh
- and 1 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06401421A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Penn State Health Milton S. Hershey Medical Center, Hershey
- University of Pennsylvania - Abramson Cancer Center, Philadelphia
- UPMC - Hillman Cancer Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT07100106The Cancer of the Pancreas Screening-5 CAPS5)Study
- University of Pennsylvania, Philadelphia
- University of Pittsburgh, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT02000089Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
- Fox Chase Cancer Center, Philadelphia
Recruiting
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT07140172A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Thomas Jefferson University - Clinical Research Institute ( Site 0056), Philadelphia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06312176A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT05123482Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT06757634A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
- Lehigh Valley Health Network (Data Collection Only), Allentown
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT05534438The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
- WellSpan York Cancer Center, York
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Alliance Cancer Specialists, Horsham
- University of Pennsylvania, Abramson Cancer Center, Perelman Center for Advanced Medicine, Philadelphia
- University of Pittsburgh (UPMC), Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06369285Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning
- Allegheny General Hospital, Pittsburgh
RecruitingObservational study
Ages 20 to 89 · Women · Updated Sep 30, 2026 · NCT07023887A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer
- AHN Allegheny General Hospital, Pittsburgh
- Allegheny General Hospital, Pittsburgh
Recruiting
Ages 20 to 89 · Women · Updated Sep 30, 2026 · NCT07698314A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05877599Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05867251EXERT-BC Protein: Protein Supplementation to Improve Body Composition After Treatment for Breast Cancer
- AHN Allegheny General Hospital, Pittsburgh
- AHN Allegheny General Hospital, Pittsburgh
Recruiting
Ages 20 to 89 · Women · Updated Sep 28, 2026 · NCT07704476Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
Recruiting
Ages 30 and older · Women · Updated Sep 25, 2026 · NCT02945579From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.